These findings were contrasted with reports of adverse dermatologic events in clinical trials of an anti-glycoprotein nonmetastatic melanoma protein B (GPNMB) mAb conjugated with MMAE, glembatumumab vedotin (CR011-vc-MMAE or CDX-011), being developed for adult cancers that express GPNMB, including melanoma and breast cancer [28,29]. This evidence concerns the gene GPNMB and breast carcinoma.